CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 889 enrolled
Drug / intervention
Escitalopram, venlafaxine, lithium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00974155
NCT00974155Phase 4Completed
CompareCT.gov

Randomised Clinical Trial Comparing Early Medication Change (EMC) Strategy With Treatment as Usual (TAU) in Patients With Major Depressive Disorder - the EMC Trial

K. Lieb·interventional·Posted Sep 10, 2009·Updated Apr 1, 2015

In Brief

A Phase 4 clinical trial evaluating Escitalopram, venlafaxine, lithium and Escitalopram, venlafaxine for Depression. Completed, enrolled 889 participants across 1 site.

Detailed Summary

The EMC trial investigates for the first time prospectively whether Major Depression Disorder patients with non-improvement after 14 days of antidepressive treatment with EMC are more likely to become remitters compared to patients treated according to current guidelines, i.e., with a medication change after 28 days of treatment in case of non-response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesGermany
CollaboratorsGerman Federal Ministry of Education and Research

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 10, 2009
Enrollment StartSep 1, 2009
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 16.8 years ago

Interventions

Escitalopram, venlafaxine, lithiumdrug

oral application, highest tolerable dose, once daily

Escitalopram, venlafaxinedrug

oral application, highest tolerable dose, once daily